Download Your Free Copy to Explore:
- The Drug Landscape – Explore the emergence of 2,045 ICMs, with a 10% increase in new assets, highlighting the shift towards novel targets and the persistent interest in PD-1 and CTLA-4 inhibitors.
- The Trial Landscape & Regulatory Announcements – Gain insights into the 1,189 new clinical trials launched this year, with a focus on adaptive trial designs, biomarker-driven patient selection, and the ongoing challenges of advancing new therapies without recent approvals.
- The Commercial Landscape & Future of Checkpoint – Understand the cautious yet strategic investment trends of 2024, where late-stage PD-1 and PD-L1 inhibitors dominate funding, while early-phase investment is funneled into emerging targets like STING and ADORA2A.
You may also be interested in...
H1 2024 Immune Tolerance Landscape Review
H1 2024 Bispecific Landscape Review
H1 2024 Checkpoint Landscape Review
H1 2024 ADC Landscape Review
ASCO 2024: Checkpoint Highlights
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.
With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.
Any questions? Get in touch
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
